The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for revolutionary treatments and significant returns is certain, the linked risks are also notable. Many of these pro